Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.25 - $8.54
Previous CloseN/A
Volume477.34K
Average Volume (3M)2.06M
Market Cap
$398.68M
Enterprise Value$74.38M
Total Cash (Recent Filing)$222.26M
Total Debt (Recent Filing)$35.29M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Oct 30, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding95,941,260
10 Day Avg. Volume1,285,337
30 Day Avg. Volume2,056,959
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-465.28
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$15.10Price Target Upside270.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Market PotentialThere is an opportunity for COMPASS to seek accelerated approval for COMP360 in treatment-resistant depression, highlighting its potential market impact.
Regulatory ProgressThe company is well positioned to benefit from industry tailwinds at the regulatory level, suggesting potential growth and success for COMPASS Pathways.
Therapy DevelopmentCOMPASS Pathways is pioneering the development of a new model of psilocybin therapy with its proprietary formulation, COMP360.
Bears Say
Market ReactionThe market’s muted reaction to the COMP005 trial results—CMPS is down 20% since the data release—misrepresents the trial’s success, which provides a validated safety baseline and a credible efficacy signal.
Stock PerformanceCMPS shares sank ~45% on the news and have barely recovered.
Trial ConcernsConcerns were raised after the negative Lykos AdComm and CRL about functional unblinding, expectation bias, selection bias, missing data, and potential trial personnel misconduct.
COMPASS Pathways News
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $2.25 and its highest was $8.54 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $398.68M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 30, 2025 which is in 69 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Jul 31, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.023.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.4.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 95,941,260 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went up 10.406%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.10 (270.10% Upside)
$15.10 (270.10% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 534.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.98%
12-Months-Change
Fundamentals
Return on Equity
-71.30%
Trailing 12-Months
Asset Growth
5.39%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally optimistic outlook for COMPASS Pathways, with significant positive results in late-stage trials and a strong financial position. However, challenges remain, particularly in achieving FDA approval and addressing trial dropouts.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$15.10
▲(270.10% Upside)
Technical Analysis
Ownership Overview
20.71% Insiders
0.08% Mutual Funds
44.77% Other Institutional Investors
31.01% Public Companies and Individual Investors